Cingulate Inc. (NASDAQ:CING – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 27,900 shares, a decline of 74.4% from the September 15th total of 108,800 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average daily volume of 3,830,000 shares, the short-interest ratio is presently 0.0 days.
Cingulate Stock Performance
CING traded up $0.39 during trading on Friday, reaching $4.84. 197,070 shares of the company were exchanged, compared to its average volume of 1,285,917. The company’s 50-day moving average is $5.88 and its two-hundred day moving average is $2.51. Cingulate has a 12-month low of $1.80 and a 12-month high of $156.00.
Cingulate (NASDAQ:CING – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($5.47) EPS for the quarter, beating analysts’ consensus estimates of ($5.64) by $0.17. Research analysts forecast that Cingulate will post -12.51 EPS for the current fiscal year.
Institutional Trading of Cingulate
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
See Also
- Five stocks we like better than Cingulate
- Stock Sentiment Analysis: How it Works
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What is Forex and How Does it Work?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.